tiprankstipranks
Antibe Therapeutics, Inc. (Otc) (ATBPF)
:ATBPF
US Market

Antibe Therapeutics (ATBPF) Income Statement

Compare
107 Followers

Antibe Therapeutics Income Statement

Last quarter (Q3 2024), Antibe Therapeutics's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q3, Antibe Therapeutics's net income was C$-4.21M. See Antibe Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 23Mar 22Mar 21Mar 20Mar 19
Total Revenue
C$ 0.00C$ 0.00C$ 9.71MC$ 9.99MC$ 9.54M
Gross Profit
C$ 0.00C$ -99.00KC$ 3.55MC$ 3.89MC$ 3.55M
Operating Expenses
C$ 20.55MC$ 25.53MC$ 27.81MC$ 21.21MC$ 15.74M
Depreciation and Amortization
C$ 99.00KC$ 99.00KC$ 478.00KC$ 571.00KC$ 416.22K
EBITDA
C$ -19.19MC$ -25.15MC$ -23.73MC$ -17.98MC$ -11.84M
Operating Income
C$ -20.55MC$ -25.53MC$ -24.71MC$ -18.92MC$ -12.19M
Other Income/Expenses
C$ 1.25MC$ 279.00KC$ -1.20MC$ -1.72MC$ -494.00K
Pretax Income
C$ -19.29MC$ -25.25MC$ -24.73MC$ -19.35MC$ -12.68M
Net Income
C$ -19.48MC$ -25.06MC$ -26.30MC$ -19.34MC$ -12.82M
Per Share Metrics
C$ ―C$ ―C$ ―C$ ―C$ ―
Basic EPS
C$ -0.37C$ -0.49C$ -0.71C$ -0.71C$ -0.60
Diluted EPS
C$ -0.37C$ -0.49C$ -0.71C$ -0.71C$ -0.60
Weighted Average Shares Outstanding
52.29M 50.77M 37.25M 27.27M 21.49M
Weighted Average Shares Outstanding (Diluted)
52.29M 50.77M 37.25M 27.27M 21.49M
Currency in CAD

Antibe Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis